MSD wins Gilead infringement case

pharmafield logo - pharma news

Merck (MSD outside the United States and Canada) has won $200 million in damages, from Gilead Sciences. It relates to methods used when developing Hepatitis C treatments. 

The jury awarded the damages as compensation for infringement, up to December 2015. The Court will hold separate proceedings, on royalties owed by Gilead, for all infringing products sold from January 2016.